Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | angiogenesis inhibito | 0.0281 | 0.2143 | 0.2143 |
Echinococcus granulosus | a disintegrin and metalloproteinase with | 0.0417 | 0.4044 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0262 | 0.1879 | 0.1879 |
Schistosoma mansoni | subfamily M12B unassigned peptidase (M12 family) | 0.0144 | 0.0223 | 0.0552 |
Echinococcus granulosus | adam | 0.0278 | 0.2102 | 0.4918 |
Loa Loa (eye worm) | hypothetical protein | 0.0844 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0135 | 0.0096 | 0.0096 |
Echinococcus multilocularis | a disintegrin and metalloproteinase with | 0.0417 | 0.4044 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0144 | 0.0223 | 0.0223 |
Loa Loa (eye worm) | hypothetical protein | 0.0337 | 0.2919 | 0.2919 |
Brugia malayi | hypothetical protein | 0.0278 | 0.2102 | 0.2102 |
Onchocerca volvulus | Papilin homolog | 0.0259 | 0.1831 | 0.5 |
Loa Loa (eye worm) | angiogenesis inhibito | 0.0147 | 0.0264 | 0.0264 |
Echinococcus multilocularis | adam 17 protease | 0.016 | 0.0454 | 0.0605 |
Schistosoma mansoni | adam (A disintegrin and metalloprotease | 0.0278 | 0.2102 | 0.5199 |
Schistosoma mansoni | subfamily M12B unassigned peptidase (M12 family) | 0.0144 | 0.0223 | 0.0552 |
Loa Loa (eye worm) | hypothetical protein | 0.0259 | 0.1831 | 0.1831 |
Schistosoma mansoni | ADAM17 peptidase (M12 family) | 0.016 | 0.0454 | 0.1124 |
Brugia malayi | ADAMTS-like protease | 0.0281 | 0.2143 | 0.2143 |
Loa Loa (eye worm) | reprolysin | 0.0144 | 0.0223 | 0.0223 |
Echinococcus multilocularis | adam | 0.0278 | 0.2102 | 0.4918 |
Schistosoma mansoni | ADAMTS5 peptidase (M12 family) | 0.0417 | 0.4044 | 1 |
Echinococcus granulosus | adam 17 protease | 0.0176 | 0.0677 | 0.1189 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 25.8 uM | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by MABA method | ChEMBL. | 22626551 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.